​

Trevi Therapeutics Stock (NASDAQ:TRVI)

ForecastOwnershipFinancialsChartTranscripts
Trevi Therapeutics by TradingView

Previous Close

$10.51

52W Range

$2.36 - $11.11

50D Avg

$8.83

200D Avg

$6.62

Market Cap

$1.28B

Avg Vol (3M)

$2.13M

Beta

0.74

Div Yield

-

TRVI Company Profile

Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

31

IPO Date

May 07, 2019

Website

TRVI Performance

TRVI Financial Summary

Dec 24Dec 23Dec 22
Revenue---
Operating Income$-51.52M$-33.92M$-29.91M
Net Income$-47.91M$-29.07M$-29.15M
EBITDA$-51.52M$-33.80M$-29.86M
Basic EPS$-0.47$-0.29$-0.45
Diluted EPS$-0.47$-0.29$-0.45

Fiscal year ends in Dec 24 | Currency in USD

Latest Earnings Call Transcripts

Q2 25Aug 08, 25 | 4:30 PM
Q1 25May 11, 25 | 4:30 PM
Q4 24Mar 18, 25 | 4:30 PM

Peer Comparison

TickerCompany
SIONSionna Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
IMTXImmatics N.V.
AMLXAmylyx Pharmaceuticals, Inc.
ATAIAtai Life Sciences N.V.
SYRESpyre Therapeutics, Inc.
NBTXNanobiotix S.A.
ZYMEZymeworks Inc.
SNDXSyndax Pharmaceuticals, Inc.
ORICORIC Pharmaceuticals, Inc.